Latest News
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
15 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that its Phase 3 KEYNOTE-C93 trial evaluating KEYTRUDA (pembrolizumab) met its primary endpoint of progression-free...
Bruker expands infection diagnostics portfolio with DISQVER platform acquisition
15 July 2026 - Life science research and diagnostics solutions provider Bruker Corporation (Nasdaq:BRKR) announced on Wednesday that it has acquired the DISQVER clinical metagenomics platform from Noscendo GmbH, expanding its next-generation sequenci...
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
15 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has granted priority review to its supplemental Biologics License Applica...
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
15 July 2026 - Swedish pharmaceutical company EQL Pharma AB (STO: EQL), which specialises in developing and selling generics, said on Wednesday it has secured approval for its melatonin-based product Mellozzan in Kazakhstan through regional partner A...
Lynk Pharmaceuticals completes patient enrolment for zemprocitinib Phase III clinical trial in ankylosing spondylitis
15 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage drug development company focused on immune and inflammatory diseases, announced on Tuesday the completion of patient enrolment in the Phase III clinical trial evaluating its core product ze...